(Q51066755)

28 March 2018

title

Serum GFAP autoantibody as an ELISA-detectable glioma marker. (English)

1 reference

28 March 2018

1 reference

Ping Wei

1

1 reference

28 March 2018

Wei Zhang

2

1 reference

28 March 2018

Liu-Song Yang

3

1 reference

28 March 2018

Hai-Shi Zhang

4

1 reference

28 March 2018

Xiao-En Xu

5

1 reference

28 March 2018

Ying-Hua Jiang

6

1 reference

28 March 2018

Feng-Ping Huang

7

1 reference

28 March 2018

Qian Shi

8

1 reference

28 March 2018

publication date

16 April 2013

1 reference

28 March 2018

published in

Tumor Biology

1 reference

28 March 2018

volume

34

1 reference

28 March 2018

issue

4

1 reference

28 March 2018

page(s)

2283-2292

1 reference

28 March 2018

https://scigraph.springernature.com/pub.10.1007/s13277-013-0770-7

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Serum proteomics of glioma: methods and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Molecularly targeted therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Sialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Cathepsin D is a potential serum marker for poor prognosis in glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Serum GFAP is a diagnostic marker for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Protein arrays as tools for serum autoantibody marker discovery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Definition of human autoimmunity--autoantibodies versus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Serum autoantibodies as biomarkers for early cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Autoantibodies as potential biomarkers for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Profiling tumor-associated autoantibodies for the detection of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Pattern of serum autoantibodies allows accurate distinction between a tumor and pathologies of the same organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Clinical validation of an autoantibody test for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Technical validation of an autoantibody test for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

An acidic protein isolated from fibrous astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Mixed oligoastrocytomas: a survival and prognostic factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0770-7

Absence of p53 autoantibodies in sera from glioma patients.

21 January 2018

1 reference

12 December 2020

Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis

1 reference

12 December 2020

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

1 reference

12 December 2020

Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.

1 reference

12 December 2020

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

1 reference

12 December 2020

Autoantibody cancer biomarker: extracellular protein kinase A

1 reference

12 December 2020

Prognostic factors in high-grade malignant glioma. A multivariate analysis of 76 cases with postoperative radiotherapy

1 reference

12 December 2020

p53 Antibodies in the sera of patients with various types of cancer: a review

1 reference

12 December 2020

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer

1 reference

12 December 2020

10.1007/S13277-013-0770-7

Identifiers

DOI

1 reference

28 March 2018

1 reference

28 March 2018